Catalyst Wire Dossier Catalyst Wire Dossier

Aumseqa

Aumolertinib mesilate · SFL Pharmaceuticals Deutschland GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Aumseqa, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: EMA Authorised: Aumseqa (Aumolertinib mesilate) — SFL Pharmaceuticals Deutschland GmbH

See pricing